|Bid||3.50 x 5000|
|Ask||5.00 x 300|
|Day's Range||3.55 - 3.80|
|52 Week Range||2.10 - 6.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The San Diego-based company said it had a loss of 43 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
For aTyr Pharma Inc’s (NASDAQ:LIFE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More...
On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...
The San Diego-based company said it had a loss of 56 cents per share. In the final minutes of trading on Thursday, the company's shares hit $3.10. A year ago, they were trading at $3.01. _____ This story ...
On a per-share basis, the San Diego-based company said it had a loss of 53 cents. For the year, the company reported a loss of $57.9 million, or $2.44 per share. In the final minutes of trading on Thursday, ...
WASHINGTON (AP) — The Supreme Court on Wednesday sided with California-based Life Technologies Corp. in a patent infringement case that limits the international reach of U.S. patent laws.
Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts ...
CEO and Director of Atyr Pharma Inc (NASDAQ:LIFE) John Mendlein bought 69,000 shares of LIFE on 12/19/2016 at an average price of $2.2 a share.